Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has issued an update.
Lumos Diagnostics has received a cash refund of A$215,485 under the Australian Government’s Research and Development Tax Incentive for its FY2024 efforts. This refund supports Lumos’ ongoing R&D in enhancing its diagnostic technology platform, which is crucial for securing partnerships and advancing point-of-care technologies.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid point-of-care diagnostic test technology, offering customized assay development and manufacturing services. The company develops, manufactures, and commercializes novel Lumos-branded point-of-care tests targeting infectious and inflammatory diseases.
Average Trading Volume: 1,248,769
Technical Sentiment Signal: Sell
Current Market Cap: A$21.71M
For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.